These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35101281)

  • 41. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
    Chen X; Geiger JD
    Cell Signal; 2020 Sep; 73():109706. PubMed ID: 32629149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
    Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
    Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
    Sun X; Ni Y; Zhang M
    Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial.
    Tirupakuzhi Vijayaraghavan BK; Jha V; Rajbhandari D; Myatra SN; John O; Ghosh A; Bassi A; Arfin S; Kunigari M; Joshi R; Donaldson L; Hammond N; Venkatesh B;
    Trials; 2020 Aug; 21(1):754. PubMed ID: 32867852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
    Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
    Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
    Pereira BB
    J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials.
    Di Castelnuovo A; Costanzo S; Cassone A; Cauda R; De Gaetano G; Iacoviello L
    Pathog Glob Health; 2021; 115(7-8):456-466. PubMed ID: 34128772
    [No Abstract]   [Full Text] [Related]  

  • 49. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.
    Celotto S; Veronese N; Barbagallo M; Ometto F; Smith L; Pardhan S; Barnett Y; Ilie PC; Soysal P; Lagolio E; Kurotschka PK; Tonelli R; Demurtas J
    Int J Infect Dis; 2021 Feb; 103():599-606. PubMed ID: 33316389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
    Risch HA
    Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
    Kashour T; Tleyjeh IM
    Med Hypotheses; 2020 Nov; 144():110198. PubMed ID: 33254507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.
    Mallat J; Hamed F; Balkis M; Mohamed MA; Mooty M; Malik A; Nusair A; Bonilla MF
    Medicine (Baltimore); 2020 Dec; 99(52):e23720. PubMed ID: 33350752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region.
    Osuagwu UL; Nwaeze O; Ovenseri-Ogbomo G; Oloruntoba R; Ekpenyong B; Mashige KP; Timothy C; Ishaya T; Langsi R; Charwe D; Kwasi Abu E; Chundung MA; Agho KE
    Afr J Prim Health Care Fam Med; 2021 Jun; 13(1):e1-e8. PubMed ID: 34212739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.
    Onori ME; Ricciardi Tenore C; Urbani A; Minucci A
    Mol Biol Rep; 2021 Mar; 48(3):2973-2978. PubMed ID: 33620659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.
    Gies V; Bekaddour N; Dieudonné Y; Guffroy A; Frenger Q; Gros F; Rodero MP; Herbeuval JP; Korganow AS
    Front Immunol; 2020; 11():1409. PubMed ID: 32714335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
    Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
    Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
    Gagnon LR; Sadasivan C; Yogasundaram H; Oudit GY
    Curr Heart Fail Rep; 2022 Dec; 19(6):458-466. PubMed ID: 36167917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
    Al-Bari AA
    Curr Drug Targets; 2020; 21(16):1703-1721. PubMed ID: 32552642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
    Zang Y; Han X; He M; Shi J; Li Y
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):775-782. PubMed ID: 32892293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.